(Q41733479)

8 October 2017

title

Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan (English)

1 reference

8 October 2017

1 reference

5

Huib N Caron

1 reference

8 October 2017

Godelieve A. M. Tytgat

2

object named as

Godelieve A M Tytgat

1 reference

8 October 2017

6

Max van Noesel

1 reference

8 October 2017

Berthe L van Eck-Smit

3

object named as

Berthe L F van Eck-Smit

1 reference

8 October 2017

author name string

Kathelijne C J M Kraal

1

1 reference

8 October 2017

Boen Kam

4

1 reference

8 October 2017

publication date

15 May 2015

1 reference

8 October 2017

published in

Pediatric Blood & Cancer

1 reference

8 October 2017

volume

62

1 reference

8 October 2017

issue

11

1 reference

8 October 2017

page(s)

1886-1891

1 reference

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

8 October 2017

cites work

1 reference

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

21 January 2018

1 reference

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage

21 January 2018

1 reference

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma

21 January 2018

1 reference

Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age.

21 January 2018

1 reference

[131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma

21 January 2018

1 reference

[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter

21 January 2018

1 reference

Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination

21 January 2018

1 reference

Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study

21 January 2018

1 reference

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study

21 January 2018

1 reference

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study

21 January 2018

1 reference

Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study

21 January 2018

1 reference

Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial

21 January 2018

1 reference

Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma

21 January 2018

1 reference

Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.

21 January 2018

1 reference

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

21 January 2018

1 reference

A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma

21 January 2018

1 reference

Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis

21 January 2018

1 reference

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma

21 January 2018

1 reference

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.25580

1 reference

8 October 2017

1 reference